Jiangsu Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hengrui Pharmaceutical Co., Ltd. traces its roots to 1970 as Lianyungang Pharmaceutical Factory and has grown into one of China's leading pharmaceutical manufacturers and traders, with a portfolio spanning anti-tumor preparations, anesthetics and anesthetic auxiliary preparations, respiratory system drugs and prophylactic biological products. Landmark achievements include its first anticancer API (Etoposide) in 1984, US FDA and Japanese PMDA API inspections through the 1990s and 2000s, launches of Oxaliplatin, Irinotecan and innovative drugs like Apatinib, international subsidiaries in the US, Japan and Germany, and a $795 million global licensing deal for its PD-1 antibody with Incyte in 2015. The company sells worldwide across North America, Europe, Asia, Australasia, the Middle East and Africa, and is recognized for its established brand, internationally approved quality standards, experienced R&D staff, large production capacity and broad product line, accepting both buyer specifications and small orders.